Member Info for GLR1990

Remember AVCT is the only company that is producing
- Self test, no medical professional required
- Pregnancy style test kit, no reagent bottle, no swabs, no control cards etc.
- Rapid, under 15 minutes
- Easy to distribute and manufacture on a large scale
- Saliva based vs intrusive nasal swab, easier collection should = higher Se/Sp, less user errors/inconsistencies
- Saliva also shown to include more of a viral load than Nasal Swab

Ultimately, this hasn't been replicated as of yet, even the new 'game changing' abbott test cannot do what the #AVCT test is proposed to do
If Abbot are targetting 50m units in October, then if #AVCT can get the test GDA approved in the next few weeks, or at least CE marked, then we can expect a monumental order from the UK GOVT alone

Still a few hurdles to overcome
- Sensitivity at least 90%
- Specificity at least 95%
- Manufacturing agreements to produce 10's millions of tests per month
- CE, WHO and FDA approval

CRUNCH TIME!

That's good news, what's the total volume over those 4 days?
Miton have 11.6m left as of the last holdings RNS, can guarantee that is coming down, do they need to notify below 3%?

'You are not going to stop in the middle of a burning building to do a cost analysis' - absolutely brilliant :')

This is really great news, NHS scotland has bought £6.7m worth of tests (500K in total)
- 12 Minute
- Portable Lab System
- Nasal Swab

'The company plans to begin shipping COVID-19 antigen tests by the end of the month, expects to produce 2 million tests in September, and will ramp to 10 million tests produced in December'
https://www.lumiradx.com/us-en/news-events/lumiradx-receives-fda-uae-for-poc-covid-19-ag-test

If they can supply 10m per month in december from a lab based, then I think its fair to say we should be supplying at least 20-30m per month by December!

Very exciting times

CSX about to open

$SONA SE 84% SP 90%

With AVCT (the only self test in development, using saliva via LFD) targetting 90% Se and 95% sp, what way will the market open across the pond?

~Just over 4 weeks to go from working with LTSM, to final clinical validation results, was one month afterwards they achieved the CE mark

We know AVCT are working with the UK-GOVT so a lot of processes working in parallel, BBI also helping with a CE mark

Preliminary clinical data IMO is already know, we are now awaiting the confirmed clinical data from LTSM - which I expect will be early to late next week all IMO DYOR

1st May 2020
Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%

https://mologic.co.uk/preliminary-clinical-performance-data-for-professional-use-covid-19-rapid-diagnostic-test/

20th April 2020
Mologic announced that it will begin manufacturing its laboratory diagnostic test for COVID-19. Following successful independent validation by the Liverpool School of Tropical Medicine and St George’s, University of London, the test has also been submitted to Public Health England for formal validation.

https://mologic.co.uk/mologic-launches-new-lab-based-covid-19-antibody-tests/

26th March 2020
Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced that it has initiated early validation of COVID-19 point-of-need diagnostic tests with the Liverpool School of Tropical Medicine and St George’s, University of London.

https://mologic.co.uk/mologic-and-partners-begin-validation-process-for-covid-19-point-of-need-diagnostic-test/

Braveheart Investment Group (AIM: BRH), reports that, further to the announcement on 23 April 2020 regarding the increase in production capacity to 2,000 litres per day by the end of May by Pharm 2 Farm Limited ("P2F") (holding 51.72%) of medical grade alcohol hand sanitiser gel, this was achieved on schedule and as planned. However, the market price of medical grade hand sanitiser has fallen steadily from an average of approximately £25 per litre in April 2020 to a current price of approximately £3 per litre. In addition, certain producers are now providing medical grade hand sanitiser free of charge to certain organisations.

In light of the steep decline in the price of medical grade hand sanitiser and the continuing demand for nanoparticle production, P2F has decided to switch its production capabilities back to nanoparticle production and to cease the production of medical grade hand sanitiser

P2F gave up on the hand sanitiser business months ago as per RNS on BRH, they couldn’t sell any as larger players had been giving it away for next to nothing

It didn't it smashed right through £2 and headed to £2.20, then we had the placing which stopped our gallop

Only thing that could stop our gallop now would be poor Se/Sp results, but by what I am reading I think they are going to be at least 90% for SE and at least 98% for SP

Really got the wind in its sails now, STEADY AS SHE GOES SIR AL!

Whoops £2 - spending too much time in penny shares
AVCT was a penny share once

Once we get past 2p

Jackie Wilson - (Your Love Keeps Lifting Me) Higher And Higher

Mine for when we hit £2 tomorrow
Marvin Gaye and Kim Weston - It Takes Two

Afternoon all

Thought I would post and it’s been a while, spend most of my time on blue bird

My current outlook
- Matt Han**** clearly excited over the AVCT test and the potential behind a 10 minute rapid POC ‘self’ saliva test
- if you actually search for the above test and check how many are in development, there are only four saliva tests currently (rapid) in development in the world, Orasure, M3, Avacta and Mologic. Mologic is now Q1 2021, Orasure backed out of Saliva and all of them aside from Avacta are not ‘self tests’ as in they still need some form of intervention from a third party instrument or personnel
- So in summary, since we are currently being clinically validated at CONDOR and with BBI, we are in pole position to be first to market with a rapid self test saliva based LFD antigen test, hence why the share price is reacting positively, so what’s next?

Well aside from lucrative partnerships with Daewoong and LG Chem, we still haven’t heard much on the BAMS test or the CV19 neutralising therapy, however if we are just focusing on the CV19 antigen test, then I’d expect the following in the next few weeks
- more manufacturing agreements
- pre orders from the U.K. GOVT (once we figure out potential capacity and confirm Se/Sp)
- Se/Sp clinical validation and CE Mark

If the sensitivity is over 95% and specificity is over 98% then nothing short of at least a billion pound MCAP Is acceptable, so ~£3.60-£4.00 - and then you can increase that depending how much demand we are expecting over the next 6-12 months

10-15m per month £3/4 a share
50-100m per month £9-12 a share
All IMO of course DYOR

CS its like catchphrase when you get down to the final square and they still cant get it
'..... erm... a...wacta?'

Ahh sorry I can't give you that say what you see if you see it say it

Ah perfect, should have checked the financial calendar
2 more trading days then, hopefully 10p+
I have been following WSG for years, was invested from 2016-2018
everytime it has gone sub 10p, it has moved back up and over
Historically you could have made a fortune buying this share sub 10p

Why is everyone so certain results are Friday?
Just asking, as I know they came out on the 15th last year, but previously they had been as late as September?
Was this announced at the AGM?

Hi Frank

It was originally, back in March/April AS was on Sky News and ITV

I suspect should the device be clinically validated in the next few weeks, that it will make national, and possibly global news

Up 20% out the blue, precisely 3pm actually
P+D, or some material?
Seems an odd day to orchestrate a P+D with the FTSE down 3%
So the Q is what has leaked?
Expecting line-up for the 02, so maybe you could be right with some 1 direction performances?

Interesting

Hi Noob

frustrating but likely to be wider market sell off IMO, GDR is down to 73p and AVCT is taking a trim back to £1.40

Never understood why people offload CV19 stocks when the market sells off

Today is big earnings day, multiple multinationals reporting H1 results so will likely be a big sell off on the FTSE 100 etc. and potentially over the pond

Again, frustrating because we could have sold yesterday and bought back today, if you are interested in 10% here and there (not bad, it all adds up)

IMO just a daily blip and should power on tomorrow with hype going into the weekend (All IMO do your own research)

Good Luck All
GLR

UPDATED JULY PLAN – Currently Conducting 4.5m tests per week in the USA
We called for rapidly expanded diagnostic testing capacity from 1 million tests per week to 3 million tests per week by June, and to 30 million tests per week by October. Today we’re at 4.5 million tests per week, but unfortunately it’s taking far too long to get to 30 million tests per week, and communities that most need them – low-income families, minorities, and highly vulnerable essential workers – find it most difficult to gain access, while elite institutions, companies, and enterprises seem to be able to access them on the private market. We need to urgently fix clinical diagnostic testing and accelerate the introduction of faster, cheaper, point-of-care screening tests to prepare for next flu season. Some say it’s impossible. Some say America has already given up. But we know it can be done, and we present here a renewed national action plan to help get there.
First, we need to massively scale up fast, cheap screening tests to identify asymptomatic Americans who are currently infected. Today the country conducts almost zero such tests, and we need at least 25 million per week for schools, health facilities, and essential workers to function safely
Today Covid-19 cases are spiking, and the trajectory in much of America is rising rapidly. In addition, we will soon enter a new cold and flu season with potentially 100 million cases of flu-like symptoms that stand to overwhelm our current testing capacity
The only alternative is more large-scale lockdowns. The price of that is too high to pay when we don’t have to, if we make smart, strategic, science-based investments now.
UK GOVT to expand testing to ~3.5m tests per week by the end of October
Monthly ~14-15m Tests
https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-17-july-2020
As we approach winter, we will need to go further – not least as many more people will show Covid-like symptoms as a result of seasonal illnesses, and therefore require a test.
So, we will further increase testing capacity to at least half a million antigen tests a day – 3.5 million antigen tests a week – by the end of October.
Demand for testing is not the only challenge that winter will bring.
It is possible that the virus will be more virulent in the winter months – and it is certain that the NHS will face the usual, annual winter pressures.

CORONAVIRUS ANTIGEN TESTING MARKET ANALYSIS
ROCKEFELLA FOUNDATION JULY 2020 UPDATE

US national covid-19 testing action plan APRIL 2020
Rockefeller Foundation
https://www.rockefellerfoundation.org/national-covid-19-testing-action-plan/
Our National Covid-19 Testing Action Plan lays out the precise steps necessary to enact robust testing, tracing, and coordination to more safely reopen our economy – starting with a dramatic expansion of testing from 1 million tests per week to initially 3 million per week and then 30 million per week, backed by an Emergency Network for Covid-19 Testing to coordinate and underwrite the testing market, a public-private testing technology accelerator, and a national initiative to rapidly expand and optimize the use of U.S., university, and local lab capacity. The plan also includes: launching a Covid Community Healthcare Corps so every American can easily get tested with privacy-centric contact tracing; a testing data commons and digital platform to track Covid-19 statuses, resources, and effective treatment protocols across states and be a clearinghouse for data on new technologies; and a Pandemic Testing Board, in line with other recommendations, to bridge divides across governmental jurisdictions and professional fields.

Total Tests Per Week (US) – Expansion from 1m Testing Per Week to 3m Per week, then expansion to 30m per week
Total Tests Per Month (Maximum Potential) ~120 million tests